List view / Grid view
8 June 2016 | By Mandy Parrett, Editorial Assistant
Global biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.
7 June 2016 | By Victoria White, Digital Content Producer
BMS and MD Anderson are to collaborate to evaluate innovative strategies for the use of Opdivo and Yervoy to treat lung cancer patients...
6 June 2016 | By Victoria White, Digital Content Producer
New data for Bristol-Myers Squibb’s Opdivo has been presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)...
1 June 2016 | By Victoria White, Digital Content Producer
New data strengthen the body of research into Opdivo, hailing it as the new standard of care in recurrent metastatic renal cell carcinoma (mRCC)...
12 May 2016 | By Victoria White, Digital Content Producer
Empliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy...
12 May 2016 | By Victoria White, Digital Content Producer
In draft guidance, NICE has said ‘no’ to Opdivo for the treatment of patients with non-squamous NSCLC whose disease has progressed after prior chemotherapy...
11 May 2016 | By Victoria White, Digital Content Producer
The approval of Opdivo + Yervoy represents the first and only approved combination of two Immuno-Oncology agents in the European Union (EU)...
10 May 2016 | By Coulter Partners
Coulter Partners was delighted to partner once again with German / Dutch diagnostics company Curetis N.V...
29 April 2016 | By 3rd Pharmaceutical Traceability Forum
Harmonize serialization plans to achieve compliance. Supply chain stakeholders must take a comprehensive view of their traceability strategy...
25 April 2016 | By Victoria White, Digital Content Producer
The designation is based on results of a Phase III trial evaluating Opdivo versus investigator’s choice of therapy in patients with SCCHN...
18 April 2016 | By Victoria White, Digital Content Producer
A Opdivo and Yervoy combination regimen demonstrated a two-year OS rate of 69% compared to 53% for Yervoy alone in BRAF wild-type advanced melanoma...
15 April 2016 | By Victoria White, Digital Content Producer
The FDA has accepted a sBLA for Opdivo that seeks to expand the use of the therapy to patients with Hodgkin Lymphoma after prior therapies...
14 April 2016 | By Victoria White, Digital Content Producer
The EC has granted approval for the use of Opdivo (nivolumab) to treat patients with the most common forms of advanced lung and advanced kidney cancer...
6 April 2016 | By Victoria White
The EC has approved Opdivo (nivolumab) for locally advanced or metastatic NSCLC after prior chemotherapy and in advanced RCC after prior therapy...
4 March 2016 | By Victoria White
Mr. Arduini is currently president and chief executive officer and director of Integra LifeSciences, a leading global medical technology company...
